Analysis of the Prevalence of Violence Suffered or Committed by Patients Suffering From Addiction in a Care Facility
NCT ID: NCT05536245
Last Updated: 2025-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4500 participants
OBSERVATIONAL
2022-01-14
2024-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypotheses: To analyze the prevalence of violence in populations suffering from addiction and the need for treatment of such violence using a robust protocol based on an anonymous questionnaire to assess the violence experienced or committed by a patient, taking into account his/her environment. This study would allow us to better understand the effects of addictions on the severity and frequency of violence, but also to implement concrete and adapted solutions in order to limit it. This study could lead to the creation of a regional Observatory of Violence related to Addictions.
Translated with www.DeepL.com/Translator (free version)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Portrayal of Hospital Alcohol Detoxification in France
NCT04973202
Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use
NCT00184223
Evaluation of Physical Activity of Patients Admitted to Addiction Service
NCT04953403
A Prospective Clinical Study of a Cohort of Patients Seeking Treatment for a Behavioral Addiction
NCT01248767
Developing Violence Prevention Therapy for Substance Abusers
NCT00551863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
i. Inclusion/End Visit (IEV): D0.Eligible patients will have been identified by the investigator, and will be recruited in the Addictology Department during their usual visit.
The inclusion visit is carried out by an investigating physician who will confirm the patient's eligibility and verify his or her ability to answer the questionnaire. It will take place in the care center. It is part of the usual care.
During this visit, the investigator will:
* Perform the usual management of the patient.
* Validate the inclusion and non-inclusion criteria.
* Issue the letter of information and non-opposition
ii. Self-questionnaire entry visit (Vfollow-up/end): from D0 to 18 months (part of the usual care). After inclusion, the subject has enough time (15-30 min) to fill in the questionnaire independently. If the subject asks for it, the doctor can give him an explanation or clarify the meaning of a question and let him answer it alone. After completing the questionnaire, the subject will have no further obligations in relation to the study.The patient will complete an electronic self-questionnaire independently.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire
To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patient over 18 years old.
* Outpatient able to express his/her non-opposition.
Exclusion Criteria
Severe neurological disorders that are incompatible with reliable data collection.
Minor patients. Pregnant women, parturients. People in emergency situations, people unable to express their consent.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gaëlle SULTAN-TIHLL
Béziers, , France
Hélène DONNADIEU
Montpellier, , France
Pascal PERNEY
Nîmes, , France
Nicolas FRANCHITTO
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Local/2021 /PP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.